Cytochrome P450 expression (CYP) in non-small cell lung cancer

Frontiers in Bioscience

Volumn 12, Issue 6, 2007, Pages 2299-2308

  Oyama, Tsunehiro ^a,b   Sugio, Kenji ^a   Uramoto, Hidetaka ^a   Kawamoto, Toshihiro ^b   Kagawa, Norio ^c   Nadaf, Sorena ^d   Carbone, David ^d   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cytochrome P450; Non small cell lung cancer; NSCLC; Survival

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; RECEPTORS, ARYL HYDROCARBON; TUMOR MARKERS, BIOLOGICAL;

EID: 36049046926     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2232     Document Type: Article

References (44)

1. Sobue, T., S. Yamamoto, M. Hara, S. Sasazuki, S. Sasaki & S. Tsugane: Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women: the JPHC study. Int J Cancer, 99, 245-51 (2002) (Pubitemid 34309482)
2. Kawajiri, K., H. Eguchi, K. Nakachi, T. Sekiya & M. Yamamoto: Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res, 56, 72-6 (1996) (Pubitemid 26010386)
3. Denissenko, M. F., A. Pao, M. Tang & G. P. Pfeifer: Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science, 274, 430-2 (1996) (Pubitemid 26353359)
4. Gonzalez, F. J. & H. V. Gelboin: Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev, 26, 165-83 (1994) (Pubitemid 24171627)
5. Windmill, K. F., R. A. McKinnon, X. Zhu, A. Gaedigk, D. M. Grant & M. E. McManus: The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res, 376, 153-60 (1997) (Pubitemid 27248598)
6. Oyama, T., T. Isse, N. Kagawa, T. Kinaga, Y. D. Kim, M Morita, K. Sugio, H. Weiner, K. Yasumoto & T. Kawamoto: Tissue-distribution of aldehyde dehydrogenase 2 and effects of the ALDH2 gene-disruption on the expression of enzymes involved in alcohol metabolism. Front Biosci, 10, 951-60 (2005)
7. Kobayashi, A., K. Sogawa & Y. Fujii-Kuriyama: Cooperative interaction between AhR.Arnt and Sp1 for the drug-inducible expression of CYP1A1 gene. J Biol Chem, 271, 1210-6 (1996)
8. Reyes, H., S. Reisz-Porszasz & O. Hankinson: Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science, 256, 1193-5 (1992)
9. Lin, P., H. Chang, W. T. Tsai, M. H. Wu, Y. S. Liao, J. T. Chen & J. M. Su: Overexpression of aryl hydrocarbon receptor in human lung carcinomas. Toxicol Pathol, 31, 2-30 (2003)
10. Mollerup, S., D. Ryberg, A. Hewer, D. H. Phillips & A. Haugen: Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res, 59, 317-20 (1999)
11. McLemore, T. L., S. Adelberg, M. C. Liu, N. A. McMahon, S. J. Yu, W. C. Hubbard, M. Czerwinski, T. G. Wood, R. Storeng, R. A. Lubet & et al.: Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst, 82, 1333-9 (1990) (Pubitemid 20238488)
12. Toussaint, C., N. Albin, L. Massaad, D. Grunenwald, O. Parise, Jr., J. Morizet, A. Gouyette & G. G. Chabot: Main drug-and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues. Cancer Res, 53, 4608-12 (1993) (Pubitemid 23304387)
13. Kushida, H., K. Fujita, A. Suzuki, M. Yamada, T. Endo, T. Nohmi & T. Kamataki: Metabolic activation of Nalkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase. Carcinogenesis, 21, 1227-32 (2000) (Pubitemid 30389351)
14. Raunio, H., J. Hakkola, J. Hukkanen, O. Pelkonen, R. Edwards, A. Boobis & S. Anttila: Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues. Arch Toxicol Suppl, 20, 465-9 (1998)
15. Shimada, T., H. Yamazaki, M. Mimura, Y. Inui & F. P. Guengerich: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther, 270, 414-23(1994) (Pubitemid 24229655)
16. Oyama, T., N. Kagawa, N. Kunugita, K. Kitagawa, M. Ogawa, T. Yamaguchi, R. Suzuki, T. Kinaga, Y. Yashima, S. Ozaki, T. Isse, Y. D. Kim, H. Kim & T. Kawamoto: Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci, 9, 1967-76 (2004) (Pubitemid 38918646)
17. Guengerich, F. P.: Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol, 39, 1-17 (1999) (Pubitemid 29222549)
18. Kivisto, K. T., E. U. Griese, P. Fritz, A. Linder, J. H akkola, H. Raunio, P. Beaune & H. K. Kroemer: Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Naunyn Schmiedebergs Arch Pharmacol, 353, 207-12 (1996)
19. Hukkanen, J., O. Pelkonen, J. Hakkola & H. Raunio: Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol, 32, 391-411 (2002) (Pubitemid 35191358)
20. Mountain, C. F. & C. M. Dresler: Regional lymph node classification for lung cancer staging. Chest, 111, 1718-23 (1997) (Pubitemid 27260108)
21. Brambilla, E., W. D. Travis, T. V. Colby, B. Corrin & Y. Shimosato: The new World Health Organization classification of lung tumours. Eur Respir J, 18, 1059-68 (2001) (Pubitemid 34092881)
22. Oyama, T., T. Osaki, N. Nose, Y. Ichiki, M. Inoue, H. Imoto, T. Yoshimatsu, M. Kodate, H. Uramoto, T. Mizoue, K. Yano & K. Yasumoto: Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma. Anticancer Res, 20, 505-10 (2000) (Pubitemid 30189710)
23. Dikov, M. M., T. Oyama, P. Cheng, T. Takahashi, K. Takahashi, T. Sepetavec, B. Edwards, Y. Adachi, S. Nadaf, T. Daniel, D. I. Gabrilovich & D. P. Carbone: Vascular endothelial growth factor effects on nuclear factor-kappaB activation in hematopoietic progenitor cells. Cancer Res, 61, 2015-21 (2001) (Pubitemid 32692022)
24. Nishimura, M., H. Yoshitsugu, S. Naito & I. Hiraoka: Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi, 122, 339-61 (2002) (Pubitemid 41364375)
25. Oyama, T., T. Kawamoto, T. Mizoue, K. Nishida, T. Osaki, K. Sugio, K. Yasumoto & T. Mitsudomi: p53 mutations of lung cancer are not significantly affected by CYP1A1 or GSTM1 polymorphisms. Int J Oncol, 11, 305-309 (1997) (Pubitemid 27305962)
26. Oyama, T., T. Kawamoto, T. Mizoue, K. Sugio, Y. Kodama, T. Mitsudomi & K. Yasumoto: Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res, 17, 583-7 (1997) (Pubitemid 27105532)
27. Mitsudomi, T., T. Oyama, T. Kusano, T. Osaki, R. Nakanishi & T. Shirakusa: Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst, 85, 2018-23 (1993) (Pubitemid 24000986)
28. Oyama, T., T. Osaki, T. Mitsudomi, R. Ogawa, R. Nakanishi, K. Sugio & K. Yasumoto: p53 alteration, proliferating cell nuclear antigen, and nucleolar organizer regions in thymic epithelial tumors. Int J Mol Med, 1, 823-6 (1998)
29. Kato, S., P. G. Shields, N. E. Caporaso, R. N. Hoover, B. F. Trump, H. Sugimura, A. Weston & C. C. Harris: Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res, 52, 6712-5 (1992)
30. Wolbold, R., K. Klein, O. Burk, A. K. Nussler, P. Neuhaus, M. Eichelbaum, M. Schwab & U. M. Zanger: Sex is a major determinant of CYP3A4 expression in human liver. Hepatology, 38, 978-88 (2003) (Pubitemid 37221681)
31. Paine, M. F., S. S. Ludington, M. L. Chen, P. W. Stewart, S. M. Huang & P. B. Watkins: Do men and women differ in proximal small intestinal CYP3A or Pglycoprotein expression? Drug Metab Dispos, 33, 426-33 (2005) (Pubitemid 40279944)
32. Shields, P. G.: Epidemiology of tobacco carcinogenesis. Curr Oncol Rep, 2, 257-62 (2000)
33. Siegfried, J. M.: Women and lung cancer: does oestrogen play a role? Lancet Oncol, 2, 506-13 (2001) (Pubitemid 33586306)
34. Thummel, K. E. & G. R. Wilkinson: In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol, 38, 389-430 (1998) (Pubitemid 28231501)
35. McFadyen, M. C., P. H. Rooney, W. T. Melvin & G. I. Murray: Quantitative analysis of the Ah receptor/cytochrome P450 CYP1B1/CYP1A1 signalling pathway. Biochem Pharmacol, 65, 1663-74 (2003) (Pubitemid 36577279)
36. Peng, H. M. & M. J. Coon: Promoter function and the role of cytokines in the transcriptional regulation of rabbit CYP2E1 and CYP2E2. Arch Biochem Biophys, 382, 129-37 (2000)
37. Gerbal-Chaloin, S., L. Pichard-Garcia, J. M. Fabre, A. Sa-Cunha, L. Poellinger, P. Maurel & M. Daujat-Chavanieu: Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide. Cell Signal, 18, 740-50 (2006) (Pubitemid 43113303)
38. Saito, S., A. Iida, A. Sekine, S. Kawauchi, S. Higuchi, C. Ogawa & Y. Nakamura: Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population. J Hum Genet, 48, 249-70 (2003) (Pubitemid 36759488)
39. Hirvonen, A., K. Husgafvel-Pursiainen, S. Anttila, A. Karjalainen & H. Vainio: The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis, 14, 85-8 (1993) (Pubitemid 23152748)
40. Uematsu, F., S. Ikawa, H. Kikuchi, I. Sagami, R. Kanamaru, T. Abe, K. Satoh, M. Motomiya & M. Watanabe: Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics, 4, 58-63 (1994) (Pubitemid 24162849)
41. Hayashi, S., J. Watanabe & K. Kawajiri: Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem (Tokyo), 110, 559-65 (1991)
42. Hege, K. M. & D. P. Carbone: Lung cancer vaccines and gene therapy. Lung Cancer, 41 Suppl 1, S103-13(2003) (Pubitemid 36819002)
43. Oyama, T., T. Osaki, T. Baba, Y. Nagata, M. Mizukami, T. So, S. Nakata, Y. Ichiki, H. Uramoto, M. Sugaya, T. Yoshimatsu, M. Morita, T. Hanagiri, K. Sugio, T. Kawamoto & K. Yasumoto: Molecular genetic tumor markers in non-small cell lung cancer. Anticancer Res, 25, 1193-6 (2005) (Pubitemid 40546789)
44. Oyama, T., A. Matsumoto, T. Isse, Y. D. Kim, S. Ozaki, T. Osaki, K. Sugio, K. Yasumoto & T. Kawamoto: Evidence-based prevention (EBP): approach to lung cancer prevention based on cytochrome 1A1 and cytochrome 2E1 polymorphism. Anticancer Res, 23, 1731-7 (2003) (Pubitemid 36750839)